LONDON (ShareCast) - (Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA).
The AIM-traded firm said the FDA's response was "detailed", and included "significant guidance" on the next steps for the clinical programme.

It said that included advice on the dosing regime.

"In addition, the FDA also provided further significant guidance on the study protocol that can be amended to improve the regulatory outcome," the board said in its statement.

"The company is currently reviewing the written response with Avion and will make a further notification in due course."

At 1342 BST, shares in ImmuPharma were down 29.31% at 4.68p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE